Publicaciones en colaboración con investigadores/as de Hospital Universitario Pío del Río Hortega (14)

2023

  1. Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

    Cancers, Vol. 15, Núm. 5

2022

  1. Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review

    Advances in Rheumatology, Vol. 62, Núm. 1

2020

  1. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients

    British Journal of Haematology, Vol. 189, Núm. 4, pp. 718-730

2019

  1. 18F-FDG PET/CT of Lung Adenocarcinoma with Ovarian Metastases

    Clinical Nuclear Medicine, Vol. 44, Núm. 5, pp. 397-398

2018

  1. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study

    Annals of Hematology, Vol. 97, Núm. 3, pp. 475-484

2016

  1. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial

    Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899

  2. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

    Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84

2015

  1. Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León

    Medicina Clinica, Vol. 144, Núm. 11, pp. 491-500

2014

  1. Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia

    BioMed Research International, Vol. 2014

2010

  1. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients

    Haematologica, Vol. 95, Núm. 5, pp. 745-751

2009

  1. High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics

    Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709

  2. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

    Blood, Vol. 114, Núm. 1, pp. 148-152

2008

  1. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

    Haematologica, Vol. 93, Núm. 12, pp. 1797-1805

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051